Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 5/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074711 | 0.90 | REN (0.39) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6873519 | 0.88 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6873741 | 0.87 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6873681 | 0.87 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6877799 | 0.87 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL10077380 | 0.84 | LAP3 (0.42) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL10074491 | 0.83 | LAP3 (0.41) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL13194683 | 0.83 | LAP3 (0.41) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6872762 | 0.82 | LAP3 (0.40) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL6874066 | 0.82 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011026781-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2011-03-10 | — | — | WO | disclosed |
| EP-2292589-A1 | Novel multifunctional peptidase inhibitors, especially for medical use | IMTM GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | PEPD, CTSC, SERPINB1 | LAP3 88/4885ANPEP 13/4885RNPEP 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.